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Abstract As cure rates in pediatric oncology have improved
substantially over the last decades, supportive care has be-
come increasingly important to reduce morbidity and mortal-
ity and improve quality of life in children with cancer.
Currently, large variations exist in pediatric oncology support-
ive care practice, which might negatively influence care. This
plea underlines the importance of development and imple-
mentation of trustworthy supportive care clinical practice
guidelines, which we believe is the essential next step towards
better supportive care practice, and thus a higher quality of
care. To facilitate international development and endorsement,
the International Pediatric Oncology Guidelines in Supportive
Care Network has been established.
Keywords Supportive care . Childhood cancer . Clinical
practice guidelines . Evidence-basedmedicine
Main Text
In the last century, medicine has changed drastically. In pediatric
oncology, major changes in cure rates in developed countries
have become visible since the introduction of chemotherapy in
the late 1940s [1]. In the early 1960s, the five-year survival rate
was 20%, this increased to 40% in the 1970s and is currently
80% in developed countries [2–4]. Although current survival
rates are excellent, the ultimate goal is for all children to be cured
of cancer. For instance, the mission statements of the St. Jude
Children’s Research Hospital (USA) and the recently founded
Dutch national Princess Maxima Center for Pediatric Oncology
both include the achievement of a greater than 90% childhood
cancer overall survival rate in the next decade as their goal [2, 5].
The main reason for the improvement in survival is the
introduction of intensive treatment protocols, encompassing
chemotherapy, radiotherapy, and/or surgery [3]. Nonetheless,
there is a cost associated with improved cure rates. This is
among other things reflected in mortality due to treatment-
related toxicity. Although progression or relapse of disease
remains the number one cause of death, treatment-related tox-
icities also contribute significantly to mortality rates. For in-
stance, a study in children with acute lymphoblastic leukemia
found that one in four deaths in their cohort was due to
treatment-related toxicity [6]. Furthermore, with cure rates
improving, fewer children will die from the cancer itself and
a higher proportion of deaths will be treatment-related [7].
Treatment-relatedmortality is not the only important metric
of antineoplastic therapy-related toxicity; treatment-related
morbidity also contributes substantially to poor quality of life
and increased costs. Treatment-related morbidity includes var-
ious physical and psychosocial side effects as a consequence
of the intensive treatment regimens.
To minimize short- and long-term morbidities and mortality
due to adverse effects of treatment, optimal supportive care is
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extremely important. Supportive care in cancer is defined by
the Multinational Association of Supportive Care in Cancer as
Bthe prevention and management of the adverse effects of can-
cer and its treatment across the cancer continuum,^ and is thus
all care provided to childrenwith cancer, apart from the primary
anti-cancer treatment (i.e. chemotherapy, radiotherapy, surgery,
and novel treatment techniques such as targeted drugs) and
follow-up care [8, 9]. Supportive care is very broad, comprising
topics such as febrile neutropenia, nausea and vomiting, alope-
cia, nutrition, and psychosocial care. Important aims of present
day pediatric oncology are to reduce short-term and long-term
toxicities and to improve quality of life for both children who
can and cannot be cured. Well-known examples are the intro-
duction of central venous access devices and the introduction of
anti-emetic prophylaxis. A challenge in supportive care is also
handling adverse effects from supportive care itself, i.e., care
that treats one problem but generates another one (usually less
severe). For example, the introduction of broad-spectrum anti-
biotic prophylaxis on the one hand lowers the frequency of
bacterial infections, but on the other hand may increase resis-
tance rates and result in invasive fungal infections.
Clinical practice guidelines
To ensure that childhood cancer patients receive optimal care,
the creation of high-quality evidence and the development of
clinical practice guidelines are essential. In the last decade, there
has been an increased interest in evidence-based guidelines. A
clinical practice guideline (CPG) is defined as a Bstatement that
includes recommendations intended to optimize patient care
that are informed by a systematic review of evidence and an
assessment of the benefits and harms of alternative care
options^ [10]. CPGs thus help the practitioner to provide the
clinical care based upon the best available evidence.
However, despite all efforts, CPGs can differ greatly in
terms of quality and applicability in practice. This is due to
several reasons, for example, variation in methodology of de-
velopment with different quality standards and hugely
protracted development cycles which results in guidelines that
are already outdated at moment of publication [11]. This led
the Institute of Medicine to write the 2011 report entitled
BClinical Practice Guidelines We Can Trust,^ which made a
substantiated plea for trustworthy CPGs [10]. In this report,
eight standards (and 20 sub standards) are described for the
development of trustworthy CPG, which comprise transpar-
ency, management of conflicts of interest, composition of a
development group, conducting a systematic review, estab-
lishing the evidence and rating the strength of recommenda-
tions, articulation of recommendations, external review, and
updating. A set of similar standards are also described in a
2012 report by the Guidelines International Network (G-I-
N), an international network of guideline developers, which
underlines their importance [12]. Adhering to these standards
in developing, and checking for these standards when endors-
ing, should lead to a base of trustworthy CPGs.
The Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) approach is an
established approach in synthesizing evidence and developing
recommendations [13]. The GRADE approach distinguishes
two types of recommendations: strong and weak. For the clini-
cian, this means that with a strong recommendation, most pa-
tients should receive this recommended course of action [14].
Thus, when CPGs are able to make strong recommendations,
these statements provide guidance for physicians who are un-
certain about the best approach to a clinical situation. Also,
these CPGs may provide justification for funding or support
in settings in which these are barriers to implementation. A
weak recommendation implies that the clinician should realize
that the appropriate choice differs per patient, and it is his or her
role to inform the patient as to make a management decision
that complements their personal values and preferences [14].
Effect of clinical practice guidelines
In many fields of medicine, care that is consistent with
evidence-based guidelines has led to improved patient out-
comes and more efficient care delivery [15–19]. Concerning
supportive care in oncology, there is also evidence that pro-
motes guideline-consistent care, for instance a recent study
showed that adherence to an evidence-based guideline in re-
lation to initiating antibiotic therapy in adult low-risk febrile
neutropenia was associated with decreased mortality [20].
Another example is the reduction of chemotherapy-induced
nausea and vomiting after highly or moderately emetogenic
chemotherapy, which has been found repeatedly [21, 22].
CPGs have several advantages, of which their potential to
improve patient health outcomes is undoubtedly the greatest
[23]. Also, the current vast amount of literature makes it im-
possible for clinicians to absorb and synthesize all available
evidence, a CPG facilitates herein and makes recommenda-
tions that are consistent with this evidence. Other advantages
of CPGs include improvement of structure and consistency of
care, improvement of patient knowledge and awareness (e.g.
through patient versions/leaflets), enhancement of public pol-
icy with regard to e.g. preventive interventions, and exposure
of gaps in contemporary scientific knowledge [18].
Clinical practice guidelines in pediatric oncology
A 2015 systematic search of MEDLINE and Embase for re-
cent evidence-based supportive care practice guidelines rele-
vant to childhood cancer identified 17 guidelines, published in
English in 2012 or more recently, that met or provisionally
met the Institute of Medicine’s 2011 definition of being based
on a systematic review (Robinson PD, Seelisch J, Kelly M,
Madden J, Kelly K, Thackray J, et al., 2015, Identification of
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evidencebased guidelines for pediatric cancer supportive care:
a systematic review, unpublished results, in progress). Of
these, only four were specifically aimed at children with can-
cer, addressing febrile neutropenia, chemotherapy-induced
nausea and vomiting, and antifungal prophylaxis [24–27].
However, for the majority of supportive care topics in pediat-
ric oncology, there are no high-quality, recent evidence-based
guidelines available to assist clinicians.
There might be several reasons underlying the scarcity of
childhood cancer supportive care guidelines. For one, in the past
decades, the majority of the pediatric oncology research has
focused on improving cure rates, which led to the remarkable
increase to a current five-year survival rate of 80% asmentioned
earlier [4]. Now that cure is so often achieved, we believe that
we should also turn to the field of supportive care and that
supportive care parameters and quality of life should be consid-
ered more often as primary clinical and research endpoints.
Another reason underlying suboptimal supportive care is that
standardization for supportive care practice is lacking [28]. For
instance, a recent study found 75% discordant supportive care
practice among all Dutch pediatric cancer centers, also in topics
for which a CPG was available (e.g. nausea and vomiting) [29].
In contrast, for primary oncological treatment, all Dutch pediat-
ric cancer hospitals have endorsed nationwide protocols, which
are set up as large (inter)national clinical trials. This further
increases the specific need for supportive care CPGs.
Developing CPGs does not automatically guarantee an im-
provement in the quality of care and health outcomes. Studies
have shown that 30 to 50% of patients do not receive the
recommended best practice [30, 31]. In addition to a high-
quality guideline development methodology, the dissemina-
tion and implementation strategies are of major importance
for the successful uptake of CPGs [30]. Besides the develop-
ment of implementation strategies, it is important to evaluate
whether the CPG is actually used in practice and if it contrib-
utes to an improvement in care. Therefore, it is important to
develop quality indicators to measure the adherence to the
CPGs [32]. In addition, development of CPGs provides an
overview of the current available evidence, while exposing
the current gaps in knowledge. This can be of great use when
defining a research agenda for the upcoming years.
iPOG network
To take maximum advantage of international effort and exper-
tise in developing and implementing supportive care CPGs,
the International Pediatric Oncology Guidelines in Supportive
Care Network (iPOG Network) has been established [33].
This voluntary international collaboration invites all who are
developing or endorsing supportive care clinical practice
guidelines in pediatric oncology to join. Current members
comprise representatives from Children’s Cancer & Blood
Disorders (C17, Canada), Children’s Cancer and Leukemia
Group (CCLG, United Kingdom), Children’s Oncology
Group (COG, United States of America), Dutch Childhood
Oncology Group (DCOG, the Netherlands), Pediatric
Oncology Group of Ontario (POGO, Canada), and The
American Society of Pediatric Hematology/Oncology
(ASPHO, United States of America).
The goal of iPOG is fourfold: (1) sharing best practices in
CPG development, (2) avoiding inadvertent duplication of
effort by sharing guideline work plans and endorsement pro-
cesses, (3) communicating evidence gaps to the research com-
munity, and (4) providing a forum for discussions regarding
guideline dissemination and implementation.
The website of the iPOG network is part of the website of
The Hospital for Sick Children (SickKids, Toronto, Canada)
and can be found at: http://www.sickkids.ca/Research/iPOG/.
Both the CPGs that are available through the iPOG network
and those currently in progress are shown in Table 1.
Table 1 Overview of CPGs of the iPOG network that are currently
available and those in progress
Available CPGs through the iPOG network
Antiemesis
Guideline for classification of the acute emetogenic potential of
antineoplastic medication in pediatric cancer patients [34], 2011
Prevention of acute nausea and vomiting due to antineoplastic
medication in pediatric cancer patients [25], 2013
Prevention and treatment of anticipatory nausea and vomiting due to
chemotherapy in pediatric cancer patients [24], 2014
Guideline for the treatment of breakthrough and the prevention of
refractory chemotherapy-induced nausea and vomiting in children
with cancer [35], 2016
Infectious diseases
Guideline for the management of fever and neutropenia in children
with cancer and/or undergoing hematopoietic stem cell transplan-
tation [26], 2012
Guideline for primary antifungal prophylaxis for pediatric patients
with cancer or hematopoietic stem cell transplant recipients [27],
2014
Guideline for the prevention of oral and oropharyngeal mucositis in
children receiving treatment for cancer or undergoing
hematopoietic stem cell transplantation [36], 2015
CPGs currently in progress in the iPOG network
Dexrazoxane use in children (expected: 2017)
Fertility preservation for female pediatric cancer patients
(PanCareLIFE, expected: 2017)
Fertility preservation for male pediatric cancer patients (PanCareLIFE,
expected: 2017)
Pain management in pediatric cancer patients (expected: 2017)
Pneumocystits jirovecii prophyalxis in pediatric cancer patients
(expected: 2017)
Prevention of acute chemotherapy-induced nausea and vomiting; fo-
cused update on aprepitant and palonosetron (expected: 2017)
School re-integration for children receiving cancer treatment (expect-
ed: 2017)
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Conclusion
With increasing survival, supportive care has become more
and more important in improving both short- and long-term
morbidities and mortality in children with cancer. We believe
that the development and use of supportive care CPGs are the
imperative next steps in bridging the gap between current
evidence and daily practice. Although significant work has
been done already, there are still many topics in supportive
care in pediatric oncology that can and should be covered
[37]. In this way, we can reduce morbidity and mortality in
children with cancer. International collaboration is essential to
avoid duplication in work and to be efficient. The groups
working together in the iPOG network will develop and im-
plement trustworthy supportive care CPGs on topics which
are important to clinicians, families, and children with cancer.
We invite all who are willing to contribute to this initiative to
collaborate.
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